Hemophilia A Drugs Market See 6% CAGR Growth and Hemophilia B Market to Grow at 4% CAGR to 2019 Forecasts New Reports at ReportsnReports.com

Share Article

The Global Hemophilia A Market 2015-2019 and Global Hemophilia B Market 2015-2019 - Industry Analysis reports are new Pharmaceuticals industry research added to ReportsnReports.com store.

Past News Releases

RSS

The 2015 reports, Global Hemophilia A Market 2015-2019 forecast global hemophilia A drugs market to grow at a CAGR of 6.25% and the report Global Hemophilia B Market 2015-2019 - Industry Analysis forecasts global hemophilia B market to grow posting a CAGR of 4.18% over the period 2014-2019. The reports, Global Hemophilia A Drugs Market 2015-2019 and Global Hemophilia B Market 2015-2019 - Industry Analysis, has been prepared based on an in-depth market analysis with inputs from industry experts.

The Complete Global Hemophilia A Market 2015-2019 Report spreads across 68 pages and support the search with 29 Exhibits is available at http://www.reportsnreports.com/reports/426939-global-hemophilia-a-market-2015-2019.html .

And the report Global Hemophilia B Market 2015-2019 - Industry Analysis spreads across 60 pages and supports the search with 28 Exhibits is available at http://www.reportsnreports.com/reports/426940-global-hemophilia-b-market-2015-2019-industry-analysis.html.

Both the reports cover the current scenario and the growth prospects of the global hemophilia A drugs market and global hemophilia B market for the period of 2015 – 2019. The market size is calculated based on the revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A and hemophilia B. In Global Hemophilia A Market 2015-2019 report, the market is also segmented based on the type of therapy.

The following companies are the key players in the Global Hemophilia A Market: Baxter International, Bayer's, CSL Behring, Novo Nordisk and Pfizer.

Other Prominent Vendors in the Hemophilia A market are: Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen Idec, Catalyst Biosciences, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Grifols, Inspiration Biopharmaceuticals, Kedrion Biopharma, Octapharma, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics and UniQure.

The report segments the Hemophilia A Market by:
Therapy: Plasma-derived therapies and Recombinant therapies
Disease Management: On-demand therapy, Prophylaxis and Inhibitors
Geographical: APAC, Europe, and Americas

Commenting on the Global Hemophilia A Market 2015 – 2019 report, an analyst said: "There are new technological advancements in terms of drug manufacturing, development, and delivery. These advances has led to the development of recombinant products. For instance, animal or human plasma proteins are not used to manufacture NovoSeven, thereby decreasing the risk of infection. The use of Fc-fusion technology has increased the half-life of Eloctate in blood, thereby improving drug action." Order a license copy of hemophilia A drugs market report at http://www.reportsnreports.com/purchase.aspx?name=426939 for US $2500.

According to the Global Hemophilia A Market 2015 – 2019 report, the development of new hemophilia A therapeutics with prolonged action is prompting market growth. Vendors are developing a number of products, which are in the pipeline stage. The anticipated approval of these products will impact the growth of the market during the forecast period.

The following companies are the key players in the Global Hemophilia B Market: Baxter, Grifols, Novo Nordisk and Pfizer.

Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen, Catalyst Biosciences, CSL Behring, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Kedrion, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics, Swedish Orphan Biovitrum, and uniQure.

The report segments the Hemophilia B Market by:
Disease Severity: Mild hemophilia B, Moderate hemophilia B and Severe hemophilia B
Disease Management: On-demand therapy, Prophylactic therapy and Inhibitor therapy
Geographical: APAC, Americas and EMEA

Commenting on the Global Hemophilia B Market 2015 – 2019 report, an analyst said: "Major vendors are entering into strategic alliances for drug development. Strategic alliances, in terms of licensing and collaboration, help vendors co-develop and commercialize drugs in different regions." Order a license copy of hemophilia B drugs market report at http://www.reportsnreports.com/Purchase.aspx?name=426940 for US $2500.

According to the Global Hemophilia B Market 2015 – 2019 report, prophylactic treatment is fast gaining popularity among physicians and patients. The treatment increases patients' quality of life in terms of physical strength. It also maintains optimum levels of clotting factors, prevent spontaneous bleeding in individuals with hemophilia B, and reduce joint damage and pains.

Further, both the reports states that the high cost of treatment leads to the discontinuation of therapy by patients, thereby hampering market growth.

About US:
ReportsnReports.com is an online market research reports library of 500,000+ reports and in-depth studies of 5000+ micro markets. Call +1 888 391 5441 with your industry research requirements or email, the details on sales at reportsandreports.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
ReportsnReports
+1 (888) 391-5441
Email >
@marketsreports
since: 06/2010
Follow >
ReportsnReports
since: 06/2011
Like >
Follow us on
Visit website